UBS Raises Valuation of Moderna: Clinical Developments Expected

UBS has upgraded its valuation of biotechnology company Moderna (MRNA). The bank noted that significant clinical data expected to be announced in the near term could positively impact the stock’s performance, reflecting growing confidence in Moderna’s R&D portfolio. UBS analysts highlighted the potential of Moderna’s pipeline beyond its current vaccine platform, including candidate vaccines for respiratory infections and cancer. In particular, the firm emphasized that the results of upcoming Phase 3 trials could serve as a catalyst for the shares. The investment bank revised its price target for MRNA upward, stressing that the company’s valuation has become more attractive under current market conditions. UBS cited Moderna’s strong cash position and advancing clinical programs as supporting long‑term growth prospects. This upgrade signals a positive outlook for MRNA shares, with investors expected to focus on the company’s forthcoming clinical data releases. UBS’s move can be seen as part of a renewed optimism in the biotechnology sector. This is not investment advice.